Clinical Study for COPD Patients Opens to Oklahoma County and Pottawatomie County Residents

Study focused on determining the impact of an investigational treatment on COPD flare-ups

BOSTON--(BUSINESS WIRE)--A new research study for chronic obstructive pulmonary disease (COPD) exacerbations is now available in Choctaw, Okla. The CRESCENDO study, by AstraZeneca, aims to determine the impact of a once-daily pill on easing symptoms, reducing flare-ups, and improving the quality of life for people with COPD.

COPD is a serious lung condition that often leads to intense exacerbations known as “flare-ups.” These flare-ups result in breathing difficulties, a diminished quality of life, and higher risks of mortality. Despite available treatments like inhalers, many COPD patients still struggle to manage their symptoms effectively. Current treatments often fall short in preventing flare-ups, improving symptoms, and reducing the need for hospitalizations.

"We recognize the urgent need to provide better treatment options for individuals living with COPD," stated Dr. Cary Carpenter, the Care Access lead investigator for this study in Choctaw. "Our community now has the opportunity to contribute to this crucial research effort, potentially changing the way we approach COPD care."

The research study is enrolling for COPD patients 40 to 80 years of age, who have a history of smoking and are at high risk of exacerbations. To learn more about this study, visit joincopdstudy.com or contact Care Access at [phone].

Care Access opened its doors in Choctaw in collaboration with local community leaders and healthcare providers seeking to make clinical studies more easily accessible to patients. The local setting provides residents of Choctaw and surrounding communities the option to participate in clinical studies close to home.

About Care Access

Care Access is a global clinical research company helping to accelerate the future of medicine. With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies. In addition to its proven track record of globally top-enrolling sites, Care Access partners with new-to-research communities and establishes high-quality research site infrastructure locally to expand access to clinical trials and increase representation.

For research sponsors, Care Access offers three core services: (1) global network of research sites, (2) community screenings to expand a study’s reach, and (3) staffing, on-demand physical space expansion, and training services to support all research sites on a study.

To learn more about active studies at Care Access, or how Care Access helps sponsors achieve enrollment and representation goals, visit www.careaccess.com.